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Background: Celiac disease (CD) is an autoimmune disorder, characterized by the presence of gastrointestinal and
multisystem symptoms, which occasionally mimic those of Irritable Bowel Syndrome (IBS) and Fibromyalgia
Syndrome (FMS). To assess the effectiveness of a Gluten-Free Diet (GFD) in seven adult female screening-detected
CD subjects, categorized as severe IBS and FMS patients.
Methods: All subjects showed villous atrophy in duodenal biopsies, were HLA-DQ2/DQ8-positive, and fulfilled the
Rome III and ACR 1990 criteria respectively for IBS and FMS classification. GFD effectiveness was assessed at baseline
and after 1 year, examining the score changes in the Tender Points (TPs) test, Fibromyalgia Impact Questionnaire
(FIQ), Health Assessment Questionnaire (HAQ), Short Form Health Survey (SF-36), Visual Analogue Scales (VAS) for
gastrointestinal complaints, pain and tiredness, drug prescriptions and tissue-Trans-Glutaminase (tTG) serum levels.
Results: At baseline, all patients had poor Quality of Life and VAS scores, a high number of TPs and drug
prescriptions, and increased tTG levels. After 1 year of GFD, all outcome measures significantly improved, with a
decrease of 51-60% in TPs, FIQ, HAQ, and VAS scales, and in the number of prescribed drugs, accompanied by an
increase of 48-60% in SF-36 Physical and Mental Component Summary scores, and a decrease of tTG to normal
values.
Conclusion: Results of this pilot study show that the adherence to a GFD by CD-related IBS/FMS patients can
simultaneously improve CD and IBS/FMS symptoms, and indicate the merit of further research on a larger cohort.
Keywords: Gluten-free diet, Celiac disease, Fibromyalgia syndrome, Irritable bowel syndrome, Health-related quality
of lifeBackground
Irritable Bowel Syndrome (IBS) is a common gastrointes-
tinal functional disease, characterized by chronic abdom-
inal pain or discomfort, along with diarrhea, constipation
(or a pattern of alternation between the two), defecation
urgency, tenesmus, bloating and abdominal distension
[1,2]. Diagnosis of IBS is based on a positive history
of gastrointestinal symptoms (Rome III criteria) in the
absence of alarm features, such as: age of onset >50 years,
weight loss, rectal bleeding, iron-deficient anemia, systemic* Correspondence: lrodrigosaez@gmail.com
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reproduction in any medium, provided the orsigns of infection, or family history of inflammatory bowel
disease or colon cancer [3].
Several comorbidities that occur more often in IBS pa-
tients than in the general population have been identi-
fied, including Fibromyalgia Syndrome (FMS), Chronic
Fatigue Syndrome (CFS), Gastroesophageal Reflux Dis-
ease (GERD), Temporo-Mandibular Joint (TMJ) dis-
order, headache, backache, genito-urinary symptoms,
anxiety and depression [4,5]. Specifically, FMS, a preva-
lent chronic widespread pain disorder affecting mainly
females (classified according to the 1990 American
College of Rheumatology [ACR] criteria) [6], occurs in
20-32% of people with IBS [7]. In turn, 32-70% of people
with FMS also meet the criteria for IBS [8,9].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(CD) was considered to be a rare disease, but has now
proved to be very common, with a fairly uniform world-
wide distribution and an average prevalence of 1-2%.
However, it is underdiagnosed, leading to its prevalence
being underestimated. Furthermore, the disease can be
associated with and/or mimicked by many other intes-
tinal and extra-intestinal diseases [10].
On the other hand, the incidence of CD in IBS pa-
tients is more than 7-fold that of the general population
[11-13]; for this reason it has been estimated that testing
IBS for CD could be cost-effective and therefore recom-
mendable in clinical practice [14].
In recent years, a possible causal link between IBS,
FMS and multi-symptomatic forms of gluten sensitivity
(CD included) has been suspected on the basis that
some cases with overlapping symptoms share similar
clinical features [15,16] and that there are some case re-
ports describing isolated patients suffering from FMS
and CD simultaneously whose symptoms resolved after
removing gluten from their diets [17,18].
The present report refers to a recent active case-
finding study for CD conducted by our group among
229 IBS subjects. 104 (45.4%) of these had associated
FMS, among whom we detected 7 CD (6.7%) patients.
These IBS/FMS/CD-associated patients were started on
a gluten-free diet (GFD) and showed a remarkable im-
provement in their digestive and systemic symptoms on
follow-up. Therefore, the main objective of the present
report was to analyze the observed clinical, analytical
and Health-Related Quality of Life (HR-QoL) changes
after 1 year on a GFD in these CD subjects.Methods
Study population and data source
During the 6-year period 2007–2012, we prospectively
studied a total of 442 consecutive patients, applying the
Rome III criteria for IBS [3] and the ACR 1990 criteria
for FMS [6] upon their first visit to the Gastroenterology
Outpatient Clinic at the Central University Hospital of
Asturias, HUCA (Oviedo, Spain). Most patients were re-
ferred from the Rheumatology and Internal Medicine
Departments of the same Hospital for the study of a
wide variety of long-standing gastrointestinal symptoms.
Diagnosis of IBS was based on a positive history of ab-
dominal discomfort or pain associated with disturbed
defecation (Rome III criteria), in the absence of obvious
alarm features. Although IBS is no longer a diagnosis of
exclusion, since there is good evidence that a positive
clinical diagnosis is sufficiently reliable [19], a battery of
tests was performed in all patients before commencing
the study, a comprehensive medical history was taken,
and a thorough physical examination and a completebroad laboratory hematological and biochemical screen-
ing were done.
In non-responders to usual therapies, in doubtful
cases, or those suspected of having other associated or-
ganic illnesses, a specific breath test was performed to
exclude possible lactose intolerance or a small bowel
bacterial overgrowth. Fecal cultures were performed as
needed to rule out parasitic infections in some patients.
Furthermore, a total colonoscopy was carried out and
random colonic biopsies were taken of patients with per-
sistent diarrhea to rule out microscopic colitis.
An immunological fecal occult blood test (iFOBT) was
done in patients aged over 50 years and in those with a
positive familial history of colon cancer in first-degree
relatives. If this iFOBT was positive, the study was com-
pleted with a total colonoscopy.
The inclusion criteria for IBS patients were: (1) Age
18 years or over but less than 65 years; (2) Positive Rome
III criteria; (3) Absence of any other associated organic
gastrointestinal disease; (4) Negative ACR 1990 criteria
for FMS. The same criteria were used to select IBS pa-
tients with associated FMS, except the last one, since, by
definition, patients had to fulfill the ACR 1990 for FMS
classification criteria.
The exclusion criteria for IBS were: (1) Age under 18
or above 65 years; (2) Incomplete or doubtful Rome III
criteria; (3) Incomplete or doubtful ACR 1990 criteria
for IBS/FMS subjects; (4) Presence of any organic
gastrointestinal disease; (5) Any abnormal finding in the
analytical screening, colonoscopy or colonic biopsies; (6)
Presence of alarm signs or symptoms; (7) Unwillingness
to participate in the study.
A total of 263 out of 442 individuals (59%) were eli-
gible to participate in the study. Thirty-four declined to
sign the written consent and were excluded. In the end,
229 subjects agreed to take part in this study. Partici-
pants were then assigned to one of two groups: the IBS
plus FMS group, comprising 104 patients who fulfilled
both the Rome III criteria for an IBS diagnosis and the
ACR 1990 criteria for FMS classification; the IBS group,
comprising the 125 age- and sex-matched, unrelated pa-
tients from the same Asturian population who fulfilled
the Rome III criteria for IBS diagnosis, but did not ex-
hibit FMS widespread pain or tender points on the skin,
and who had negative ACR 1990 criteria.
These 229 subjects were invited to participate on a
voluntary basis, after signing a specific informed consent
form. The Study Project was approved by the Research
and Ethics Committee of the HUCA, following the prin-
ciples included in the modified Declaration of Helsinki.
Outline of the study protocol
Each volunteer underwent a clinical evaluation, includ-
ing an updated medical history, a thorough physical
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battery test, and a broad analytical panel.
Duodenal biopsy studies
An upper gastrointestinal endoscopy with at least 4 duo-
denal biopsies was performed in all the patients included
in this case finding/screening, following the usual meth-
odology employed in our Service for CD diagnosis. Sam-
ples were routinely stained with Hematoxylin-Eosin
(HE) and anti-CD3 immunohistochemical monoclonal
antibodies to verify the presence and to account for
the number of intraepithelial lymphocytes (IELs). These
were in turn quantified per 100 epithelial cells. Sam-
ples were studied by two expert pathologists from the
HUCA and classified into the following types: Stage 0:
Histologically normal duodenum; Stage 1: Increased IEL
infiltration with a total count ≥ 25% epithelial cells; Stage 2:
Crypt hyperplasia and diffuse chronic inflammatory
infiltrate of the lamina propria; Stage 3: Villous atrophy,
subdivided into three categories: a) mild, b) moderate,
and c) severe, according to the histological classification
for CD described by Marsh in 1992 [20] and modified
by Oberhüber et al. [21].
Tender points (TPs)
TPs were identified and quantified by digital pressure on
the 18 anatomical locations recommended by the ACR
1990 study [6].
Physical, mental, psychological, social functioning and
quality of life questionnaires
To measure their physical, mental, psychological, and
social functioning, each patient filled out the self-
administered Spanish version forms of the Fibromyalgia
Impact Questionnaire (FIQ), the Health Assessment
Questionnaire (HAQ), and the Short Form Health
Survey (SF-36).
FIQ metric
This 10-item instrument measures physical functioning,
work status, depression, anxiety, sleep, pain, stiffness, fa-
tigue, and wellbeing on a rating-structured question-
naire, yielding scores between 0 and 80 points. Total
FIQ scores are used to define FMS severity, with scores
of 0–39, 40–59, and 60–80 corresponding to mild, mod-
erate, and severe FMS, respectively [22].
HAQ metric
The 20-item disability scale of the HAQ measures a pa-
tient’s difficulty and need for help and assistive devices
in activities of daily living. Each item is scored on a
4-point scale, the highest representing maximum impair-
ment: 0 = able to do without any difficulty, 1 = some
difficulty, 2 =much difficulty, and 3 = unable to do [23].SF-36 metric
The 36 multi-item scale of the short form SF-36 covers
8 aspects of physical and mental health: (1) Physical
functioning (PF); (2) Role physical (RF); (3). Bodily pain
(BP); (4) General health (GH); (5) Vitality (VT); (6) Social
functioning (SF); (7) Role emotional (RE); (8) Mental
health (MH).
The scores of these 8 items are aggregated into two
weighted, norm-based Physical and Mental Component
Summaries (PCS and MCS, respectively), which take
values from 0 (poorest health) to 100 (best health sta-
tus). No reliable relationship has been established be-
tween presence and severity of disease and SF-36 scores.
For guidance, the published mean values (and standard
deviations) for adults in the general Spanish population
are 73.0 ± 27.8 (PCS) and 74.4 ± 24.4 (MCS) [24].
To evaluate the severity of digestive symptoms and the
amount of pain and fatigue experienced by the patients
we used three appropriate types of Visual Analogue
Scales (VAS) [25-27].
Cell blood count and coagulation studies were per-
formed with an automated Abbott Hematology Analyzer
(Cell Dyn 3500), and the Coagulation Analyzer ACL
3000 (Menarini), respectively. Biochemical tests were
performed on a Hitachi Modular automated analyzer
SXA-PPBD (Roche) using enzymatic or kinetic methods
to measure urea, glucose, total protein, albumin, C-
reactive protein, calcium, folate, vitamin B-12, creatinine,
creatine kinase, rheumatoid factor, lipid profile, liver
function, IgG, IgA and IgM immunoglobulins, iron me-
tabolism, thyroid function, and to carry out a urinalysis
with microscopic examination of the sediment.
Anti-nuclear antibodies (ANAs) and anti-thyroid per-
oxidase (anti-TPO) antibodies were measured in each
participant. In cases with altered liver function test re-
sults, anti-mitochondrial antibodies (AMAs) were
assessed by indirect immunofluorescence assay in the
Hep-20-10 cell line (Euroimmun, Lübeck, Germany).
Anti-IgA tissue Trans-Glutaminase subtype 2 (tTG)
antibodies were measured with an ELISA kit from Phadia
Diagnostics (Upsala, Sweden).
HLA-DQ2 genetic markers (DQA1*0501 and DQB1*0201
alleles) were determined by a polymerase chain reaction
(PCR) with a Protrans® HLA Celiac Disease Domino System
(Protrans, Ketsch, Germany) kit. The HLA-DQ8 haplotype
was characterized in anHLA-DQ2-negative case with villous
atrophy.
Statistical analysis Descriptive statistics were derived for
continuous variables (mean, standard deviation, and range)
and categorical variables (percentages). Normally distrib-
uted continuous outcome measures were analyzed using
Student’s t tests, or ANOVA followed by a post hoc Fisher’s
test, as appropriate. The chi square contingency test (or
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categorical data. All statistical tests were carried out using
SPSS 15.0 (SPSS Inc, Chicago, IL, 2009). Two-sided P
values < 0.05 were considered to be statistically significant.Results
Of the 229 patients, 125 (54%) were diagnosed with IBS;
104 were female (84%), and the mean age was 51 ±
8 years. The mean duration of symptoms was 29 ±
5 years. Based on stool consistency, they were divided
into 3 groups: 74 with constipation, 33 with diarrhea,
and 18 mixed.
The remaining 104 (46%) were diagnosed with IBS +
FMS; 93 were female (89%), with a mean age of 50 ±
8 years. The mean duration of symptoms was 29 ±
7 years. Distribution with respect to stool consistency
was as follows: 68 with constipation, 25 with diarrhea,
and 9 mixed. No clinical differences were observed be-
tween the two groups.
Seven of the 104 IBS + FMS patients were diagnosed
with CD (7%). All were females, with a mean age of 49 ±
12 years (range, 34–68 years). Increased serum levels
of tTG, were present in all patients, with mean values of
60 ± 52 U/ml (range, 12–150 U/ml). Genetic markers of
CD susceptibility were positive in all cases (HLA-DQ2
in 6, and HLA-DQ8 in 1 case).
From a total of 104 FMS patients, the histopatho-
logical analysis of duodenal biopsies revealed 58 cases
(56%) showing features of lymphocytic enteritis corre-
sponding to a Marsh type 1 lesion.
Mild-to-moderate villous atrophy (Marsh 3a-3b) was
observed in the duodenal biopsies in all CD cases (7%).
A positive familial history of CD was found in two cases,
and of FMS in one case.
Finally, we found 39 cases (37%) presenting either
minimal histological changes or a completely normal
duodenal histology.
The seven CD patients exhibited a combination of the
following gastrointestinal symptoms: diffuse abdominal
pain/discomfort, constipation, diarrhea, alternating diar-
rhea/constipation, bloating and heartburn. In the vast
majority of cases, patients started noticing these symp-
toms in their 20s. In addition, all complained about a
number of common FMS symptoms, including wide-
spread soft-tissue pain, abnormal fatigue, sleep distur-
bances, cognitive dysfunction, etc. The mean duration of
FMS-related symptoms was 7 ± 4 (range, 4–15) years.
All patients had very poor HR-QoL profiles, as mea-
sured by FIQ, HAQ and SF-36 tests, and were conse-
quently categorized as severely affected FMS patients.
In addition, they presented a number of other associ-
ated diseases, including osteoporosis and temporo-
mandibular joint disorders (TMJs).All patients had been taking several drugs, predomin-
antly analgesics, proton-pump inhibitors (PPIs), anti-
depressants and anxiolytics for a long time.
Hematological and general biochemical analyses were
within normal ranges in all seven patients at the time of
inclusion.
After 1 year of GFD, all the selected outcome measure
scores (TPs, FIQ, HAQ, SF-36; VAS for gastrointestinal,
complaints of pain and tiredness, and prescribed drugs
for symptom control) improved over 50% with respect
to baseline (P < 0.001), and the serum concentrations of
tTG decreased substantially until normalization in all
cases (P < 0.05). TPO and AMAs steadily dropped to
normal values in all cases as well (Table 1).
Mean changes and standard deviations observed in the
different measures of HR-QoL included in the study, be-
fore and after a GFD, are shown in (Figure 1).
We also found a clear improvement in the individual
and global components of the SF-36 scores when com-
paring the baseline values with the results obtained
1 year after the introduction of the GFD, although the
values did not reach those observed in the general Spanish
population (Figure 2).
Discussion
The most relevant finding of the present study was the re-
markable improvement achieved for all outcome measures
after one year of uninterrupted GFD in 7 CD females pre-
viously categorized as severe IBS/FMS patients recruited
through case-finding among IBS and FMS patients.
Curiously, the clinical presentation of these “IBS/FMS
CD-associated” patients exhibited a repetitive chrono-
logical sequence, usually starting as gastrointestinal relaps-
ing disorders, frequently misclassified as IBS, when the
patients were in their 20s and 30s, becoming multisystem
“FMS-like” complaints around their mid-40s. Notably,
about 30% of these patients mentioned having other first-
degree relatives diagnosed with CD. In addition, they
scored very poorly in TPs and HR-QoL tests, and as this
negative clinical picture would suggest, these patients re-
ported not only frequent use of healthcare services and
multiple drug prescriptions, but also low rates of medica-
tion adherence due to drug intolerance, lack of effective-
ness, or drug-related adverse effects. Finally, an excess of
associated diseases and a high prevalence of circulating
autoantibodies were documented.
After 1-year of sustained GFD, a very significant de-
crease (ranging from 51 to 60%) in TPs, FIQ, HAQ and
VAS mean scores, and a positive change of 48% and 60%
in the SF-36 physical and mental scores, respectively, were
observed. For example, the FIQ mean score decreased
from more than 60 to less than 39 (i.e., from “severe” to
“mild” FMS); the mean HAQ score category changed from
“much difficulty” to “able to do with some difficulty”; the
Table 1 Comparison of global outcome measures, comparing basal (pre) and after one year (post) on a GFD: Change is
calculated as the percentage improvement in scores
Pre-GFD Post-GFD Change (%) P
TPs (scale 0–18) 16.3 (2.4) 8.0 (1.6) 8.3 (51) < 0.001
FIQ (scale 0–80) 74.3 (2.9) 36.6 (4.0) 37.7 (51) < 0.001
HAQ (scale 0–3) 1.7 (0.6) 0.7 (0.3) 1.0 (52) < 0.001
VAS digestive (scale 0–100) 47.8 (2.4) 19.1 (0.8) 28.7 (60) < 0.001
VAS pain (scale 0–10) 8.0 (0.5) 3.9 (1.0) 4.1 (52) < 0.001
VAS fatigue (scale 0–10) 7.9 (0.3) 3.9 (0.8) 4.0 (51) < 0.001
SF36-PCS (scale 0–100) 27.4 (3.6) 40.4 (5.1) +13.0 (48) < 0.001
SF36-MCS (scale 0–100) 17.4 (2.9) 27.8 (3.3) +10.4 (60) < 0.001
Prescribed drugs (N) 6.6 (1.5) 3.3 (0.5) 3.6 (55) < 0.001
tTG2 (U/ml) 60.4 (52.2) 0.7 (0.2) 59.7 (98) < 0.05
Data are expressed as mean and standard deviation. TPs Tender Points. FIQ Fibromyalgia Impact Questionnaire. HAQ Health Assessment Questionnaire. VAS Visual
Analogue Scale. SF-36 Short Form Health Survey; PCS Physical Component Summary; MCS Mental Component Summary. N number. tTG-2 Tissue
Trans-Glutaminase-2. P < 0.05, significant; P < 0.001, highly significant.
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vere” to “slight/moderate” intensity; the VAS for the
amount of pain changed from “very bad” to “not too bad”,
and a similar result was obtained for the amount of fatigue
patients felt. Alongside this clinical improvement, a sig-
nificant decrease of 55% in both the number and doses of
prescribed drugs was reported, and interestingly, the un-
pleasant manifestations of some associated diseases, such
as chronic urticaria, improved significantly. On the other
hand, the basal tTG-2, TPO and AMA serum levels stead-
ily dropped to normal values in all patients.Figure 1 Changes in outcome measures, comparing baseline and afteCD is a multisystem autoimmune disorder related to a
permanent intolerance of gluten (a protein found in
bread, pasta, cookies, pizza crust and many other foods
containing wheat, barley or rye) that affects 1-2% of the
population (mainly females) worldwide, with subjects
generally being carriers of one of the two HLA-II geno-
types, DQ2 and DQ8. In these subjects, gliadin peptides
trigger an aberrant immune response, resulting in the
production of tTG autoantibodies, and an immune-
mediated chronic inflammation of the small bowel mu-
cosa, characterized by villous atrophy, intraepithelialr one year of GFD.
Figure 2 Comparison of mean SF-36 scores for patients at
baseline and after one year of GFD compared with those in the
healthy general Spanish population [24]. Abbreviations: PF,
Physical Functioning; RP, Role Physical; BP, Bodily Pain; GH, General
Health; VT, Vitality; SF, Social Functioning; RE, Role Emotional; MH,
Mental Health; PCS, Physical Component Summary; MCS, Mental
Component Summary.
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tions of CD may appear at any age, with gastrointestinal
and/or extra-intestinal systemic symptoms, although
some diagnoses can be made in asymptomatic individ-
uals. Notably, a gluten-free diet (GFD) results in
complete clinical remission and full recovery of the in-
testine in the vast majority of CD patients [28,29].
On the other hand, FMS is a complex chronic pain
syndrome affecting around 2% of the population (mainly
females) worldwide, characterized by widespread soft-
tissue pain, generalized tender points, abnormal fatigue,
non-restorative sleep, and a variety of additional symp-
toms. Its pathogenesis remains elusive, and no analytical
test or imaging techniques for objective diagnosis are
currently available. Thus, an exclusion diagnosis must be
used when other typified diseases are ruled out after an
appropriate evaluation study in patients fulfilling the
American College of Rheumatology (ACR) 1990 criteria
for FMS [6]. Another troubling aspect of FMS is the lack
of effective therapy for controlling its symptoms, which
makes it a major source of personal, family and social
disturbances, and leads to heavy use of health care ser-
vices, increased work absenteeism, disability and early
retirement [30-32].
The striking results of the present trial suggest that a
triggering gluten-related autoimmune inflammatory
process within the gastrointestinal tract may end up
contributing to the onset or increasing the well-
documented central nervous system sensitivity respon-
sible for FMS disorder in some CD- or gluten-sensitive
individuals [30]. This hypothesis appears to be consistent
with the increased prevalence of FMS described in
women with different chronic inflammatory processes
within the gastrointestinal tract [31,32], and with the fact
that our patients reported a long-term history ofgastrointestinal complaints preceding the onset of gener-
alized FMS symptoms by decades. Specifically, the co-
morbid triad of IBS, chronic fatigue and musculoskeletal
pain has been considered striking, and other authors
have suggested that it may point to an underlying com-
mon food hypersensitivity-related mechanism [15].
ANAs were positive in three cases, but none fulfilled
the ACR 1982 criteria required for a diagnosis of Sys-
temic Lupus Erythematosus [32]. High serum levels of
anti-TPO were found in two cases with minor and tran-
sitory thyroid function test result alterations, and AMA
antibodies were positive in one case presenting mild ele-
vations of serum liver enzymes without clinical manifes-
tations of liver disease.
Autoantibodies are a characteristic feature of CD, and
it is thought that they contribute to the extra-intestinal
organ involvement by attacking multiple body cells, fi-
nally causing inflammatory damage through an antigen-
antibody interaction at the vascular level. In fact, 75% of
CD patients have anti-TG2/TG3/TG6 circulating anti-
bodies in blood vessels [33,34], and although anti-tTG2
antibodies are primarily deposited in the intestine, they
have also been found in a diversity of other tissues such
as skin, oral mucosa, muscle, liver, cerebellum, lymph
nodes, etc., whereas anti-gliadin antibodies have been re-
ported to bind to Purkinje cells and dorsal root ganglion
neurons [35,36].
The findings of the present trial may have some biases
arising from the small number of patients involved and
from the lack of reliable biomarkers for IBS and FMS
diagnosis/follow-up (compulsorily based on question-
naires, which are inevitably subjective). Our results are
nevertheless promising, because apart from providing
new research perspectives on IBS and FMS, a relatively
poorly understood area of scientific knowledge, the de-
tection of misdiagnosed CD-related IBS/FMS cases
would lead to the implementation of a GFD, a simple
therapeutic action that could kill two birds with one
stone by simultaneously improving gastrointestinal and
extra-intestinal symptoms. Furthermore, in the long
term, it could prevent further CD-associated complica-
tions in patients and undiagnosed relatives at risk of de-
veloping overt CD.
Conclusions
In IBS/FMS patients, the varied extra-intestinal clinical
presentations sometimes make CD diagnosis challenging.
It is therefore important for clinicians of all subspecialties
to be aware of the diverse symptoms and diseases associ-
ated with CD so they can consider, at very least, perform-
ing serological tests for celiac disease. When these are
positive, it would also be useful to perform appropriate
HLA tests and duodenal biopsies before proceeding with a
gluten withdrawal diet in these patients.
Rodrigo et al. BMC Gastroenterology 2013, 13:157 Page 7 of 8
http://www.biomedcentral.com/1471-230X/13/157Abbreviations
CD: Celiac disease; FMS: Fibromyalgia syndrome; GFD: Gluten-free diet;
TPs: Tender points; FIQ: Fibromyalgia impact questionnaire; HAQ: Health
assessment questionnaire; VAS: Visual analogue scale; tTG: Tissue
trans-glutaminase; HR-QoL: Health-related quality of life; HLA: Human
leukocyte antigens; ACR: American college of rheumatology.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LR, study design, diagnosis and review of patients, analysis of results, and
initial and final revision of the manuscript; IB, study design, analysis of results
and initial and final writing of the manuscript: JB, study design, analysis of
HR-QoL results, and initial and final review of the manuscript; FdeS, valuable
suggestions about the study design, analysis and interpretation of results,
review of the scientific content and approval of the English language of the
final manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors are indebted to Ms. Sue Edelstein of the NIEHS Arts and
Photography for designing the figures for the study that provide an
at-a-glance visual overview of the results. The authors would also like to
acknowledge the work of Mr. Marino Santirso in reviewing and correcting an
earlier English draft of the manuscript, and to Dr. Phil Mason for his excellent
contribution to the final English revision of the paper.
Funding
The funders had no role in the study design, data collection or analysis,
decision to publish, or preparation of the paper.
Author details
1Gastroenterology, Central University Hospital of Asturias (HUCA), Celestino
Villamil, s/n, 33006, Oviedo, Principality of Asturias, Spain. 2Biomedical
Research Office of the Principality of Asturias, FICYT, c/Rosal 7–bis, 33009
Oviedo, Principality of Asturias, Spain. 3Medicine Department, Psychiatry Area,
University of Oviedo, Juan Clavería 6, 33006, Oviedo, Principality of Asturias,
Spain. 4National Institute of Environmental Health Sciences Research Triangle
Park, Durham, NC 27709-2233, USA.
Received: 12 May 2013 Accepted: 4 November 2013
Published: 9 November 2013
References
1. Talley NJ: Irritable bowel syndrome. Intern Med J 2006, 36:724–728.
2. Mayer EA: Clinical practice. Irritable bowel syndrome. N Engl J Med 2008,
358:1692–1699.
3. Drossman DA, Dumitrascu DL: Rome III: New standard for functional
gastrointestinal disorders. J Gastrointestin Liver Dis 2006, 15:237–241.
4. Whitehead WE, Palsson O, Jones KR: Systematic review of the comorbidity
of irritable bowel syndrome with other disorders: what are the causes
and implications? Gastroenterology 2002, 122:1140–1156.
5. Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye FA: Migraine,
fibromyalgia, and depression among people with IBS: a prevalence
study. BMC Gastroenterol 2006, 6:26.
6. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL,
Tugwell P, Campbell SM, Abeles M, Clark P, et al: The american college of
rheumatology 1990 criteria for classification of fibromyalgia: report of
the multicenter criteria committee. Arthritis Rheum 1990, 33:160–172.
7. Lubrano E, Iovino P, Tremolaterra F, Parsons WJ, Ciacci C, Mazzacca G:
Fibromyalgia in patients with irritable bowel syndrome. An association
with the severity of the intestinal disorder. Int J Colorectal Dis 2001,
16:211–215.
8. Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M,
Fich A, Buskila D: Fibromyalgia in the irritable bowel syndrome: studies of
prevalence and clinical implications. Am J Gastroenterol 1999,
94:3541–3546.
9. Wallace DJ, Hallegua DS: Fibromyalgia: the gastrointestinal link. Curr Pain
Headache Rep 2004, 8:364–368.10. Fasano A, Berti I, Gerarduzzi T, et al: Prevalence of celiac disease in at-risk
and not-at-risk groups in the United States: a large multicenter study.
Arch Intern Med 2003, 163:286–292.
11. Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BM, Moayyedi P: Yield of
diagnostic tests for celiac disease in individuals with symptoms
suggestive of irritable bowel syndrome: systematic review and
meta-analysis. Arch Intern Med 2009, 169:651–658.
12. Sanders DS, Carter MJ, Hurlstone DP, Pearce A, Ward AM, McAlindon ME,
Lobo AJ: Association of adult coeliac disease with irritable bowel
syndrome: a case–control study in patients fulfilling ROME II criteria
referred to secondary care. Lancet 2001, 358:1504–1508.
13. Zwolinska-Wcislo M, Galicka-Latala D, Rozpondek P, Rudnicka-Sosin L, Mach
T: Frequency of celiac disease and irritable bowel syndrome coexistance
and its influence on the disease course. Przegl Lek 2009, 66:126–129.
14. Spiegel BM, DeRosa VP, Gralnek IM, Wang V, Dulai GS: Testing for celiac
sprue in irritable bowel syndrome with predominant diarrhea: a
cost-effectiveness analysis. Gastroenterology 2004, 126:1721–1732.
15. Zipser RD, Patel S, Yahya KZ, Baisch DW, Monarch E: Presentations of adult celiac
disease in a nationwide patient support group. Dig Dis Sci 2003, 48:761–764.
16. Berstad A, Undseth R, Lind R, Valeur J: Functional bowel symptoms,
fibromyalgia and fatigue: a food-induced triad? Scand J Gastroenterol
2012, 8–9:914–919.
17. Taubman B, Mamula P, Sherry DD: Prevalence of asymptomatic celiac
disease in children with fibromyalgia: a pilot study. Pediatr Rheumatol
Online J 2011, 9:11.
18. Prada A, Isasi C, Campos J, Otón T, Polo J, García B, Mulero J: Coeliac
disease and chronic pain: report of three cases diagnosed in a
rheumatology unit, with remission of pain after gluten-free diet.
Rheumatology 2010, 49(suppl. 1):i75–i76.
19. Yawn BP, Lydick E, Locke GR, Wollan PC, Bertram SL, Kurland MJ: Do
published guidelines for evaluation of irritable bowel syndrome reflect
practice? BMC Gastroenterol 2001, 1:11.
20. Marsh MN: Gluten, major histocompatibility complex and the small
intestine. A molecular and immunobiologic approach to the spectrum of
gluten sensitivity (‘celiac sprue’). Gastroenterology 1992, 102:330–354.
21. Oberhüber G, Granditsch G, Vogelsang H: The histopathology of celiac
disease. Time for a standardized report scheme for pathologists.
Eur J Gastroenterol Hepatol 1999, 1:1185–1194.
22. Rivera J, González T: The fibromyalgia impact questionnaire: a validated
Spanish version to assess the health status in women with fibromyalgia.
Clin Exp Rheumatol 2004, 22:554–560.
23. Esteve-Vives J, Batlle-Gualda E, Reig A: Spanish version of the health
assessment questionnaire: reliability, validity and transcultural equivalency.
Grupo para la Adaptación del HAQ a la Población Española. J Rheumatol
1993, 20:2116–2122.
24. Alonso J, Regidor E, Barrio G, Prieto L, Rodríguez C, de la Fuente L:
Population reference values of the Spanish version of the health
questionnaire SF-36. Med Clin (Barc) 1998, 111:410–416.
25. Jaeschke R, Singer J, Guyatt GH: A comparison of seven point and visual
analogue scales. Data from a randomized trial. Control Clin Trials 1990,
11:43–51.
26. Langley GB, Sheppeard H: The visual analogue scale: its use in pain
measurement. Rheumatol Int 1985, 5:145–148.
27. Wewers ME, Lowe NK: A critical review of visual analogue scales in the
measurement of clinical phenomena. Res Nurs Health 1990, 13:227–236.
28. Crowe SE: In the clinic. Celiac disease. Ann Intern Med 2011, 154(9). ITC5-1-
ITC-15/quiz ITC5-16. doi:107326/0003-4819-154-9-2011050030-01005.
29. Rodrigo L: Celiac disease. World J Gastroenterol 2006, 12:6585–6593.
30. Smith HS, Harris R, Clauw D: Fibromyalgia: an afferent processing disorder
leading to a complex pain generalized syndrome. Pain Physician 2011,
14:E217–E245.
31. Neumann L, Buskila D: Epidemiology of Fibromyalgia. Curr Pain Headache
Rep 2003, 7:362–368.
32. Yunus MB: The prevalence of fibromyalgia in other chronic pain
conditions. Pain Res Treat 2012, 2012:584573. doi:10.1155/2012/584573.
33. Hochberg M: Updating the american college of rheumatology revised
criteria for the classification of systemic lupus erythematosus. Arthritis
Rheum 1997, 40:1725.
34. Korponay-Szabo IR, Halttunen T, Szalai Z, Laurila K, Király R, Kovács JB, Fésüs
L, Mäki M: In vivo targeting of intestinal and extraintestinal
transglutaminase 2 by celiac autoantibodies. Gut 2004, 53:641–648.
Rodrigo et al. BMC Gastroenterology 2013, 13:157 Page 8 of 8
http://www.biomedcentral.com/1471-230X/13/15735. Patinen P, Aine L, Collin P, Hietanen J, Korpela M, Enckell G, Kautiainen H,
Konttinen YT, Reunala T: Oral findings in coeliac disease and Sjögren’s
syndrome. Oral Dis 2004, 10:330–334.
36. Hadjivassiliou M, Boscolo S, Davies-Jones GA, Grünewald RA, Not T, Sanders
DS, Simpson JE, Tongiorgi E, Williamson CA, Woodroofe NM: The humoral
response in the pathogenesis of gluten ataxia. Neurology 2002, 58:1221–1226.
doi:10.1186/1471-230X-13-157
Cite this article as: Rodrigo et al.: Clinical impact of a gluten-free diet on
health-related quality of life in seven fibromyalgia syndrome patients
with associated celiac disease. BMC Gastroenterology 2013 13:157.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
